Search

Displaying results 3271 - 3280 of 8469 in total
  1. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394] … [L23394] Prior to this approval, therapy consisted of symptomatic treatment such as hyperhydration, inhibitors of crystallization, [pyridoxine], and renal transplant.

  2. Drug

    Triflupromazine

    go.drugbank.com/drugs/DB00508
    ApprovedVet approved

    A phenothiazine used as an antipsychotic agent and as an antiemetic.

  3. Drug

    Recombinant Super-Compound Interferon

    go.drugbank.com/drugs/DB15752
    Investigational

    This interferon has antiviral and antitumor activity.

  4. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

  5. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.

  6. Drug

    N-Acetylglucosamine

    go.drugbank.com/drugs/DB00141
    ApprovedInvestigationalNutraceutical

    The N-acetyl derivative of glucosamine.

  7. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance. … This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741]

  8. Drug

    Interferon alfacon-1

    go.drugbank.com/drugs/DB00069
    ApprovedWithdrawn

    This protein has a molecular weight of 19,434 daltons. … Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology.

  9. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  10. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.